Pfizer Inc. and BioNTech stated on Thursday that they had requested U.S. regulators to approve emergency use of their COVID-19 vaccine for youngsters aged from 5 to 11, Pfizer stated in a submit on Twitter.
“We and @BioNTech_Group formally submitted our request to @US_FDA for Emergency Use Authorization (EUA) of our #COVID19 vaccine in youngsters 5 to <12,” the corporate stated.
“We’re dedicated to working with the FDA with the last word purpose of serving to defend youngsters towards this critical public well being risk.”
Pfizer has but to make a full submission to Well being Canada, however has despatched in preliminary trial knowledge to the Canadian regulator.
The corporate has beforehand stated it hopes to make a full submission by mid-October.
Learn extra:
Pfizer sends preliminary youngsters’ COVID-19 vaccine trial knowledge to Well being Canada
(Reporting by Susan Heavey, Enhancing by Timothy Heritage)
— With recordsdata from International Information.
View hyperlink »
